Amber Bio raises $26m to advance first-of-its-kind RNA editing platform
Amber Bio, a trailblazing biotechnology company, has launched with an oversubscribed $26 million seed financing round to pioneer multi-kilobase gene editing platforms. This innovative approach ... Read More
Ocugen gets FDA nod to begin OCU400 clinical trial in retinitis pigmentosa
Ocugen said that the US Food and Drug Administration (FDA) has accepted its investigational new drug application (IND) to launch a first-in-human clinical trial of ... Read More